🟢 Cue Biopharma is trading 8.08% up with no announcement explaining the move identified

Cue Biopharma is trading at $19.80, up 8.08%, with no new company-specific announcement identified to explain the October 28 move.

• Recent coverage instead centers on September’s CUE-221 Phase 2 results.
• Biotech rose 2.18%, providing a supportive sector backdrop but not establishing the cause of Cue Biopharma’s larger gain.
• Major market indices were nearly flat in the supplied context, so broader-market strength is not a clear explanation.